Activity and research directory projects
The directory lists antimicrobial resistance (AMR) activities and research and displays whether they are in progress or completed. Use the filters and search to help refine your query.18 activities or research projects found
- select to clear
- 15 April 2020Avian pathogenic E. coli (APEC) is a cause of poultry mortality and disease and poses a major economic threat to poultry farming. It may also pose a risk to human health and is linked with urinary tract infections and sepsis. As the first to provide whole genome sequence data on APEC in Australia, Ausgem has found that Australian APEC carry few antimicrobial resistance genes unlike APEC found overseas. This highlights the effectiveness of Australia’s strict regulation of antimicrobial use in agriculture.AusGEM (Partnership between University of Technology and NSW Department of Primary Industries).
- 15 April 2020Ausgem is using genomic sequencing to characterise Escherichia coli that cause urinary tract infections and sepsis in Australian hospitals. Our studies are focussing on the carriage of mobile antimicrobial resistance (AMR) genes and virulence genes in these cohorts and comparing these elements with those circulating in food production systems and from environmental and wildlife sources enabling policy makers to make informed regulatory choices regarding antimicrobials and biosecurity.AusGEM (Partnership between University of Technology and NSW Department of Primary Industries).
- 15 April 2020Intensive pig production introduces a significant number of bacteria, most notably E. coli, into the environment through pig faeces. E. coli can cause illness in both humans and livestock and poses a risk to the profitability of animal agriculture. By performing whole genome sequencing of E. coli and the other microbes frequently found in pigs, AusGEM is helping track the spread of resistance genes through agriculture, humans, and the environment.University of Technology and NSW Department of Primary Industries Partnership (AusGEM)
- 2 August 2019The two main objectives of this project is: 1) to engineer micro- and nano-surfaces with enhanced anti-microbial properties and 2) to develop novel technologies to include such functional micro and nano-surfaces on "real-life" objects, overcoming the limitation of micro and nanotechnologies to small areas and flat surfaces.Monash University
- 9 July 2019Neisseria gonorrhoeae, the etiological agents of gonorrhoea, is now resistant to all available antibiotics. In the last three years, we have discovered how Neisseria bacteria escape the immune system to cause disease. We are now focused on harnessing this knowledge to develop new options that activate the immune system to control infections.Monash University
- 1 July 2019This project aims to employ novel approaches to discover new-generation polymyxin antibiotics targeting the deadly Gram-negative ‘superbugs’. Novel lead molecules have been licensed to Qpex Biopharma (US) for IND-enabling evaluations with a Phase-I study aimed at 2020.Monash University and I (Jian Li, Professor, PhD) am the principal investigator. My project is currently funded by the American National Institutes of Health (NIH). More information at https://www.monash.edu/discovery-institute/news-and-events/news/2019-articles/us-biopharmaceutical-company-licenses-monash-university-superbug-drug-discovery
- 29 June 2019Glycopeptide antibiotics – which include vancomycin – are last-resort antibiotics used in the clinic to treat serious Gram-positive bacterial infections. In this project, my team are utilising a novel chemo-enzymatic formation route that we have pioneered to generate and explore the properties of new vancomycin derivatives. This will allow us to explore the structure/ function relationships of these crucial antibiotics and to overcome growing bacterial resistance against these compounds.Monash University
- 29 June 2019In this project, my team is developing a new approach to tackling antimicrobial resistance that exploits alternate mechanisms to overcome bacterial infections through augmentation of host immune responses and removal of bacterial evasion mechanisms. Our simultaneous “drug-immune” therapies will provide highly synergistic bacterial killing utilising existing antibiotic therapeutics, thus underlining the feasibility of future clinical application of such approaches.Monash University
- 27 June 2019We are working with clinicians in the Center for Innovative Phage Applications and Therapeutics at the University of California in San Diego. Phage therapy is frontier medicine, and has FDA approval for use in hospitals in the USA. Isolating clinically-effective "cocktails" is a challenge that can only be met by collaboration between research scientists trained in phage biology (Monash) and clinicians with experience in clinical deployment (UCSD).Monash University.
University of California in San Diego.
- 27 June 2019We have engaged with partners in Wenzhou, China to analyze the recent rise in AMR in their hospitals. In 2019, we opened the Monash BDI-WMU Alliance in Clinical and Experimental Biomedicine on the campus of Wenzhou Medical University. Initial assessments of one species of bacteria reveals that 15 years ago, less than ten patients per annum were infected, all of which responded to off the shelf antibiotics. Last year, 990 patients had infections s, with ~1 in 3 being AMR.Biomedicine Discovery Institute, Monash University, Australia.
Wenzhou Medical University, China.